

XPhyto Therapeutics Corp.

08:25 17 Sep 2019

XPhyto Therapeutics closes acquisition of German narcotics company Vektor Pharma

XPhyto Therapeutics Corp (CSE:XPHY), a medical cannabis company, said Tuesday that it has closed the share purchase agreement to acquire Vektor Pharma TF GmbH, a German narcotics manufacturer.

In a statement, the Vancouver-based company said it also completed an equipment purchase agreement with a Vektor Pharma-affiliated company.

Vektor Pharma, which is located 170 kilometers west of Munich, specializes in thin therapeutic films, such as skin patches and oral strips, and possesses a slate of narcotics licenses covering traditional and cannabis-related medications. Vektor's various narcotics licences include authorizations related to conventional and cannabis-related prescription medications, including but not limited to: Buprenorphine, cannabis, Dronabinol, Fentanyl, Hydromorphone, Oxycodone, and THC.

READ: XPhyto Therapeutics acquires German narcotics company Vektor
 "The Vektor transaction will accelerate XPhyto's medicinal cannabis import into Germany and its drug delivery expertise, both of which are a critical part of our near-term revenue generation strategy," said XPhyto CEO Hugh Rogers in a statement.

"Further, with vape-based delivery systems now associated with significant potential health risks, XPhyto is extremely pleased to combine assets and expertise with Vektor, a specialist in thin-film drug delivery systems. XPhyto is well positioned to capitalize on the next generation of cannabis investment opportunities, primarily clinical validation of safe and effective medicine and emerging European markets," he added.

In line with the agreement, XPhyto Therapeutics will pay roughly €350,000 in cash, plus 200,000 shares of stock, and about €400,000 in units of capital in the company at C\$1 per unit due upon closing. Each unit consists of a share and one warrant. The common shares are subject to a three-year escrow matrix. The warrants are exercisable into one share of the company at an exercise price of C\$1 per share for a period of three years from closing. The company also issued a pair of convertible debentures worth €200,000 and €150,000 respectively.

Pricing of the securities set out in the agreements was established pursuant to a price reservation filed with the Canadian Securities Exchange on August 6. In connection with the transaction, a consulting fee of 200,000 shares will be paid to an arms-length consultant on closing.

XPhyto is based in Vancouver but has its sights set on European markets. The company also owns Bunker Pflanzenextrakte GmbH, a German cannabis cultivation and extraction company.


Contact Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: @UttaraProactive

Price: 2.26

Market Cap: \$137 m

1 Year Share Price Graph



Share Information

Code: XPHY

Listing: CSE

52 week	High	Low
	3.55	1.1

Sector: Pharma & Biotech

Website: www.xphyto.com

Company Synopsis:

XPhyto Therapeutics Corp.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of XPhyto Therapeutics Corp. named herein, including the promotion by the Company of XPhyto Therapeutics Corp. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).